Flavoxate HCI en es it fr

Flavoxate HCI Brand names, Flavoxate HCI Analogs

Flavoxate HCI Brand Names Mixture

  • No information avaliable

Flavoxate HCI Chemical_Formula


Flavoxate HCI RX_link

No information avaliable

Flavoxate HCI fda sheet

Flavoxate HCI msds (material safety sheet)

Flavoxate HCI Synthesis Reference

No information avaliable

Flavoxate HCI Molecular Weight

1140.24 g/mol

Flavoxate HCI Melting Point

No information avaliable

Flavoxate HCI H2O Solubility

Practically insoluble

Flavoxate HCI State


Flavoxate HCI LogP


Flavoxate HCI Dosage Forms

Injection (50 mg vials to be reconstituted prior to injection)

Flavoxate HCI Indication

For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis.

Flavoxate HCI Pharmacology

Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis.

Flavoxate HCI Absorption

No information avaliable

Flavoxate HCI side effects and Toxicity

During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day).

Flavoxate HCI Patient Information

Flavoxate HCI Organisms Affected

Aspergillis, Candida and other fungi